Literature DB >> 905632

Estimation of the systemic availability and other pharmacokinetic parameters of naltrexone in man after acute and chronic oral administration.

M J Kogan, K Verebey, S J Mule.   

Abstract

First pass metabolism, metabolic clearance, volume of distribution and steady state plasma levels were estimated in man following acute and chronic 100 mg oral doses of naltrexone. Essentially no statistical differences was observed in these values between the acute and chronic physiologic state. The values for the first pass effect were 79.6 +/- 4.6% and 78.0 +/- 3.0% for acute and chronic treatment respectively. From our pharmacokinetic data an apparent chronic release rate (ACRR) for a sustained release preparation of naltrexone was calculated as 11.8 microgram/kg/hr. In practice a release rate of one half the ACRR should be sufficient to provide continuous antagonism of 25 mg i.v. heroin. In conclusion our data clearly indicate that naltrexone is an effective and safe narcotic antagonist in man.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 905632

Source DB:  PubMed          Journal:  Res Commun Chem Pathol Pharmacol        ISSN: 0034-5164


  7 in total

1.  Bioavailability prediction based on molecular structure for a diverse series of drugs.

Authors:  Joseph V Turner; Desmond J Maddalena; Snezana Agatonovic-Kustrin
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.200

Review 2.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of narcotic agonist-antagonist drugs.

Authors:  R E Bullingham; H J McQuay; R A Moore
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

4.  Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm.

Authors:  Margaret Rukstalis; Christopher Jepson; Andrew Strasser; Kevin G Lynch; Kenneth Perkins; Freda Patterson; Caryn Lerman
Journal:  Psychopharmacology (Berl)       Date:  2005-01-29       Impact factor: 4.530

5.  Naltrexone-3-salicylate (a prodrug of naltrexone): synthesis and pharmacokinetics in dogs.

Authors:  M A Hussain; E Shefter
Journal:  Pharm Res       Date:  1988-02       Impact factor: 4.200

Review 6.  Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.

Authors:  Mellar Davis
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 7.  Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence.

Authors:  J P Gonzalez; R N Brogden
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.